Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

One purpose of this study is to determine if taking droxidopa after eating will have an effect on how the body processes (absorbs and eliminates) the drug in healthy elderly subjects. Another purpose of this study is to see how the body processes (absorbs and eliminates) one 300mg capsule compared to three 100mg capsules. This study will also evaluate how well the body processes (absorbs and eliminates) and tolerates droxidopa when a 300 mg capsule is given 3 times a day for a total dose of 900 mg over the course of one day.

Droxidopa is used to treat low blood pressure upon standing in patients with diseases of the nervous system, to prevent low blood pressure in patients with kidney disease during hemodialysis (removal of waste products of the blood), and to treat frozen gait (walking, stepping or running) and dizziness upon standing in patients with Parkinson's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome

NCT00977171

Chronic Fatigue Syndrome Orthostatic Hypotension Neurally Mediated Hypotension +1 more

TERMINATED PHASE2

Pharmacokinetics of the Basel Phenotyping Cocktail Combination Capsule

NCT03247699

CYP450 Phenotyping

COMPLETED NA

Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

NCT05961384

Hypertension

COMPLETED PHASE1

Effects of Food on the Bioavailability and Pharmacokinetic Profile of Itasetron After a Single Oral Dose in Healthy Male Subjects

NCT02259985

Healthy

COMPLETED PHASE1

Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects

NCT01477619

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a two-part study. Part I is a randomized, open-label, three-period crossover study in 24 healthy, elderly, male or female subjects. Subjects will be allocated to one of three treatment sequences according to a randomization schedule prepared prior to the start of the study. Each subject will receive a single, oral dose of three 100 mg capsules of droxidopa with 240 mL of water either in the fasted state (Treatment A) or immediately following the consumption of a standardized high-fat meal (Treatment B) and a single, oral dose of one 300 mg capsule of droxidopa with 240 mL of water in the fasted state (Treatment C) on Days 1, 4, and 7. Subjects will be discharged from the research clinic on Day 8 after completing all posttreatment follow-up assessments and will return to the research clinic approximately 1 week later for Part II of the study. Part II of the study is an open-label design where all subjects will receive three doses of 300 mg droxidopa (three 100 mg capsules/dose) at 4 hour intervals and will be followed for a concurrent 24 h period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Symptomatic Neurogenic Orthostatic Hypotension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fed Dosing

Subjects fed a high calorie, high fat meal prior to receiving 3 x 100mg capsules

Group Type ACTIVE_COMPARATOR

Droxidopa

Intervention Type DRUG

3 capsules each containing 100 mg droxidopa, given once

Fasted Dosing

Subjects fasted prior to receiving 3 x 100mg capsules

Group Type ACTIVE_COMPARATOR

Droxidopa

Intervention Type DRUG

3 capsules each containing 100 mg droxidopa, given once

Bioequivalence

Subjects fasted prior to receiving 1x 300mg capsule

Group Type ACTIVE_COMPARATOR

Droxidopa

Intervention Type DRUG

One capsule containing 300 mg droxidopa, given once

TID Dosing

Droxidopa 300 mg given TID

Group Type ACTIVE_COMPARATOR

Droxidopa

Intervention Type DRUG

3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Droxidopa

One capsule containing 300 mg droxidopa, given once

Intervention Type DRUG

Droxidopa

3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals

Intervention Type DRUG

Droxidopa

3 capsules each containing 100 mg droxidopa, given once

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Provide written consent on an IRB-approved Informed Consent Form (ICF), prior to any study-specific evaluation. Subjects should have the ability to read and understand the ICF, ask for any clarifications from the study staff, and be able to comply with all planned study procedures.
2. Male or female ≥65 years of age.
3. Body mass index (BMI) between 18 and 35 kg/m2, inclusive.
4. If female, not pregnant (or lactating), as evidenced by a negative serum pregnancy test, and is surgically sterile (hysterectomy, bilateral ovariectomy, or bilateral tubal ligation), or at least 2 years postmenopausal.
5. Ability and willingness to abstain from alcohol from 48 h prior to the first dose until the completion of the study.
6. No clinically significant abnormalities on the basis of medical history, physical examination, and vital signs unless currently controlled with medical treatment (e.g., a stable medication dosing regimen).
7. Computerized, 12-lead ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations, as judged by the investigator.
8. All values for hematology, clinical chemistry, and urinalysis are normal or if abnormal-are deemed not clinically significant as judged by a physician investigator with documented agreement from the Medical Monitor.
9. Nonsmoking or have quit smoking at least 6 months prior to dosing.

Exclusion Criteria

1. Presence of active or recurring clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease not currently controlled with medical treatment (e.g., a stable medication dosing regimen).
2. Presence of an active malignancy of any type other than nonmelanomatous skin malignancies.
3. History of relevant drug and/or food allergies.
4. Recent history (past 5 years) of alcohol abuse or drug addiction.
5. Required use of concomitant medications that could confound the PK or safety evaluation, such as medications that affect GI function (including proton pump inhibitors or metoclopramide) or vasoconstricting agents (e.g., ephedrine, dihydroergotamine, or midodrine), -triptans (e.g., sumatriptan, naratriptan, zolmitriptan, rizatriptan), halogen-containing anesthetics (e.g., cyclopropane, or halothane), catecholaminecontaining preparations (e.g., isoprenaline), non-selective MAOIs, ergotamine derivatives (except for anti-Parkinson medications), or any drugs with anti-hypertensive properties that in the investigator's opinion, could significantly contribute to the subject's orthostatic hypotension.
6. Participation in an investigational drug study within 30 days prior to study drug administration.
7. Donated a unit of blood (500 mL) or plasma within the 30-day period prior to the initial dose of study medication or who intend to donate blood or plasma within a 30-day period following the final dose of study medication.
8. Positive screen for drugs of abuse (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines) or alcohol.
9. Positive screen for urine cotinine.
10. Positive screen for hepatitis B surface antigen.
11. Positive screen for antibodies to hepatitis C virus.
12. Positive screen for antibodies to human immunodeficiency virus (HIV-1/HIV-2).
13. Acute illness within 5 days prior to drug administration.
14. History of coagulation disorder, thrombocytopenia, bleeding tendency, or gastrointestinal bleeding.
15. Professional or ancillary personnel involved in the study.
16. In the opinion of the investigator, not suitable for entry into the study.

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes